Pipeline

Designated Regions in Asia-Pacific,
the Middle East and North Africa

Designated Asian Regions

Mainland China, Hong Kong, Macau and Taiwan

China

Overseas

Product	Rights Authorized Region*	Indication	Clinical Trial Approval	Phase I	Phase II	Phase III	Marketing Application	Marketed	Major Marketed Regions*
									CN	US	EU	JP
Sucroferric Oxyhydroxide Chewable Tablets		For the control of sP levels in adults with CKD on hemodialysis or peritoneal dialysis, and for the control of sP levels in paediatric patients 9 years of age and older with CKD stages 4-5 or CKD on dialysis							√ 2023.2	√	√**	√
Methotrexate Injection		Severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids							√ 2023.3		√
		Active rheumatoid arthritis in adult patients							√ 2024.7		√	√
Tildrakizumab Injection		For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy							√ 2023.5	√	√	√
Diazepam Nasal Spray		For the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older							√ 2023.6	√
Methylthioninium Chloride Enteric-coated Sustained-release Tablets		A diagnostic agent to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy							√ 2024.6		√
Ruxolitinib phosphate cream		For the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients							√ 2026.1	√	√
		For the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable								√
Desidustat Tablets		For treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients							√ 2026.3
Silevimig Injection		Passive immunization in adults following rabies virus exposure							√ 2026.6
		Passive immunization following suspected rabies virus exposure in children and adolescents aged 2 to < 18 years
Loberamisal for Injection (Y-3 for Injection)		For the treatment of acute ischemic stroke
Vecantoxatug Injection		Passive immunization against tetanus
Comekibart Injection (MG-K10)		For the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
		For the treatment of adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms remain inadequately controlled after treatment with intranasal corticosteroids
		Asthma, Prurigo nodularis, Chronic spontaneous urticaria, AD in adolescents
		Eosinophilic esophagitis, Chronic rhinosinusitis with nasal polyps, Chronic obstructive pulmonary disease
Benzgalantamine Gluconate Enteric-coated Tablets (ZUNVEYL)	***	For treating mild to moderate dementia of the Alzheimer’s type in adults								√
ABP – 671	****	Gout and hyperuricemia
Cyclosporine Eye Drops 0.09%		Increasing tear secretion in patients with keratoconjunctivitis sicca (dry eye)								√	√
Povorcitinib Phosphate Tablets (povorcitinib)		Hidradenitis suppurativa
		Non-segmental vitiligo
		Prurigo nodularis
CF101		Psoriasis
CF102		Hepatocellular carcinoma
		Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis
XF – 73		Prevention of post-surgical staphylococcal infections

* Major Marketed Regions indicate where products are approved. CMS’s rights are stated by Rights Authorized Region. CMS has NO development, commercialization or other product rights in unauthorized regions.
** Sucroferric Oxyhydroxide Chewable Tablets have been approved in Europe for the treatment of patients aged 2 years and older.
*** The rights authorized region of ZUNVEYL includes Asia (excluding Japan and the Middle East region) and other designated territories.
**** Taiwan Region is not included in the rights authorized region of ABP-671.
Please refer to local prescribing information for more information, including full safety information, on CMS’s marketed medicines, or on medicines marketed by CMS’s collaboration partners.
Updated as at 6 July 2026